I’ve previously written about Arbutus’ patent disputes with Moderna and Pfizer. In Arbutus’ case against Pfizer, the court recently conducting a claim construction hearing. Before that hearing, Pfizer argued that many of Arbutus’ patents are “indefinite.” The court held it was premature for Pfizer to make this argument, but Pfizer nonetheless established that when the case reaches summary judgment, it will rely upon the doctrine of indefiniteness to prevail against Arbutus. What is indefiniteness in patent law? Are Arbutus’ patents indefinite? How viable is Pfizer’s “indefiniteness” defense?
Read MoreOn August 26, Moderna issued a press release announcing it will be filing suit against Pfizer and BioNTech for patent infringement. Both Moderna and Pfizer/BioNTech sell Covid-19 vaccines that is based upon mRNA technology. Moderna is accusing Pfizer/BioNTech’s Covid-19 vaccine, Comrinaty®, of infringing Moderna’s patents covering certain features of Moderna’s mRNA technology. (At the time of publishing this post, Moderna’s complaint had not yet been filed. Once the complaint is filed, I will update the post.)
Read MoreModerna faces a new patent lawsuit related to its Covid vaccine. On March 17, Alnylam Pharmaceuticals commenced two separate patent lawsuits—one against Moderna and another against Pfizer. Both suits claim that the Covid manufacturers’ vaccines are infringing a patent owned by Alnylam. So what are Alnylam’s lawsuits all about?
Read MoreA number of companies have announced candidates for a COVID-19 vaccine, including Moderna Therapeutics ($MRNA), AstraZeneca ($AZN), Johnson & Johnson ($JNJ) and Novovax ($NVAX). We looked into the existing landscape of patents that cover many of the existing candidates.
Read More